ABSTRACT. We investigated the relationship between cartilage oligomeric matrix protein (COMP) levels in synovial fluid (SF), serum and urine and the development of osteochondral damage and osteophyte (OP) formation following intraarticular fractures of the carpus in racehorses in order to assess the clinical usefulness of COMP as a diagnostic biomarker of developmental osteoarthritis (OA). Two monoclonal antibodies (mAb clones 2A11 and 3C8) raised against equine COMP were shown to be capable of detecting the molecule in serum and urine as well as SF. Fifty-one samples were obtained from 26 OP-positive (OP(+)) and 25 OP-negative (OP(-)) racehorses with carpal bone fracture, in whom OP was ascertained arthroscopically and radiographically. The COMP measurements obtained using the two mAbs were highly correlated with each other in SF, serum, or urine. Horses with OP(+) showed a significantly higher [urinary COMP (µg)]/[urinary creatinine (mg)] ratio (4.94 ± 5.10 and 1.46 ± 1.19, using mAbs 2A11 and 3C8, respectively) than OP(-) horses (2.80 ± 1.72 and 0.93 ± 0.49, respectively). The relationship between serum and urine COMP levels and the period from injury to surgery were extrapolated using a polynomial expression. Measurement of COMP, especially in urine, has potential as a predictive marker of advanced OA following carpal bone fractures in racehorses. KEY WORDS: COMP, equine, fracture, osteoarthritis, urine.
Cartilage oligomeric matrix protein (COMP), an abundant non-collagenous extracellular matrix protein in cartilage [1] , plays an important role in the construction of collagen bundles and networks, being likely involved in determination of fibril diameter and/or orientation [2, 3] and interaction with other extracellular matrix molecules [4] . A recent study has also suggested that association of COMP with granulin-epithelin precursor could be required for chondrocyte proliferation [5] . COMP may also play a role in the pathogenesis of osteoarthritis (OA) as a factor secreted by chondrocytes to ameliorate matrix breakdown at the late stage of OA [6] . In human OA, measurement of COMP in serum and synovial fluid (SF) has been proposed as a helpful biomarker for predicting disease-mediated damage to joint cartilage [7, 8] . The serum COMP level is reportedly higher in patients with OA than in healthy volunteers [9] . The serum level of COMP is significantly correlated with the Western Ontario and McMaster Universities index pain scale for the lower limbs, and is higher in patients with bilateral knee OA than in unilaterally affected patients [10] . Another study has suggested that serum COMP level at the baseline could be useful for predicting the course of OA, progressors showing higher average values than nonprogressors [11] .
In studies of horses, we have demonstrated enhanced degradation of COMP in SF, and suggested that COMP fragmentation in SF could be useful for monitoring equine OA in combination with ELISA measurements [12] . Subsequently, we investigated the clinical usefulness of the serum baseline COMP level as a diagnostic marker of OA in racehorses; however, we did not obtain any clear-cut evidence such as a significant correlation of the COMP level in serum to that in SF, as well as to joint pathology or prognosis. There may be specific reasons why serum COMP may be a less sensitive indicator of joint deterioration in equine OA. Exercise-induced up-regulation of COMP turnover might be one factor that would complicate the detection of changes in serum COMP concentration due to OA pathology in horses [13] . Also, differences in OA pathology, described as a multifactorial disease secondary to fracture, osteochondrosis, degenerative joint disease, and septic arthritis in different joints, should be taken into consideration in biomarker analysis. In a previous study involving urinary COMP analysis in cases of intraarticular fracture [14] , we found positive correlations between COMP levels in urine and gelatinase activities in SF. Prior to this investigation, we had two hypotheses: the first was that the urine COMP level as a marker of proteolysis in osteoarthritic SF might increase with progression of advanced OA after intraarticular fracture, and the second was that limiting our analysis to cases of carpal fracture would minimise any effects of differences in pathology on markers present in serum as well as urine samples. Measurement of urinary COMP, which is positively correlated with matrix metalloproteinase activity in SF, would allow discrimination of advanced OA after carpal fracture. In OA pathology, cartilage degeneration and osteophyte formation are pathognomonic. Osteophyte (OP) formed by an abnormal kinetic load is associated with intraarticular fracture, inflammation or trauma of intercarpal ligaments and the insertion of ligaments and tendons to bone. Therefore, OP formation is thought to represent a process of repair around/under the site of a fracture. OP produced as a result of abnormal kinetic load on articular supporting tissue would form earlier intraarticular fracture. This cartilage degeneration and OP with OA can be estimated radiographically and arthroscopically. In the present study, we investigated the relationship between the severity of OA using OP as an indicator of OA, and the levels of COMP in SF, serum and urine as a diagnostic biomarker of OA development after carpal joint fracture in racehorses.
MATERIALS AND METHODS

Samples:
The study samples were obtained from 51 Thoroughbred racehorses, all of which had osteochondral fractures of the carpal joints. The fractures were confirmed by radiography to be located in the left (23 cases), right (25 cases), and both (3 cases) carpal joints. Fragments were removed arthroscopically from the distal radius in 31 cases, the radial carpus in 13, the third carpus in 11, and the intermediate carpus in 12. The cases were divided into osteophyte positive (OP(+))(26 horses) and osteophyte negative (OP(-)) (25 horses) groups with and without osteophytes ascertained arthroscopically and radiographycally, respectively. The cases were divided into four grades depending on the degree of cartilage or bone change (grade 1:no or minimal change in 12 cases, grade 2:mild chage in 19 cases, grade 3:moderate change in 17 cases, and grade 4:severe and bone loss in 3 cases). Urine and serum samples were obtained at the time of anesthesia induction, and samples of synovial fluid were obtained at the time of arthroscopic surgery. All of the horses were determined to be free of any other diseases including renal failure and uropathy, based on preoperative assessment of blood and urine. The samples were centrifuged, and the supernatants were stored at -70°C until assay. Prior to assay, all SF samples were pretreated with hyaluronidase (H3506, Sigma Chemical Co., St. Louis, MO, U.S.A.) according to Neidhart et al. [15] .
Preparation of equine COMP antigen and monoclonal antibodies: COMP antigen was prepared from equine articular cartilage as described previously [16] . The purity of the preparation was analysed by sodium dodecyl sulphate-polyacrylamide gel electrophoresis (SDS-PAGE) and immunoblotting with mAbs 12C4 [17] and 14G4 [12] , which recognise equine cartilage COMP. The monoclonal antibodies against equine COMP antigen were prepared as described previously [12] . Briefly, six-week-old female BALB/c mice were inoculated every 2 weeks with a total of 4 injections of equine cartilage COMP (50 µg of COMP/ mouse). The first immunization was by intraperitoneal injection of the antigen mixed with Freund's complete adjuvant (Sigma F5881). At the following two booster immunizations, the mice were intraperitoneally injected with COMP in incomplete Freund's adjuvant (Sigma F5506). At the last immunization, four days before fusion, half of the antigen (25 µg) was injected intraperitoneally and the rest intravenously. Splenocytes from the immunized mice were isolated and fused with the murine myeloma cell line P3U1 (071095, Japan Health Sciences Foundation, Osaka, Japan). Hybridoma supernatants were subsequently screened by a direct enzyme-linked immunosorbent assay (ELISA) for the presence of mouse immunoglobulins and then for the presence of antibodies against COMP. Culture media from immunoglobulin-positive wells were tested for COMPbinding antibodies by ELISA using microtiter plates coated with equine cartilage COMP (5 µg/ml). Positive colonies of hybridomas were subcloned at least 4 times by the limiting dilution method; the culture media were further examined by immunoblotting against reduced and non-reduced COMP antigens. Two hybridoma clones (2A11 and 3C8, 1 × 10 7 cells) were intraperitoneally injected into 12-week-old male BALB/c mice previously injected with 0.5 ml of Pristane (Sigma P9622). Ascitic fluids were harvested 2 to 3 weeks later, and cells and debris were removed by centrifugation at 60,000 × g at 4°C for 1 hr. The globulins were purified using Econo-Pac Protein A Cartilage (BioRad Laboratories, Alfred Nov Drive, Hercules, CA, U.S.A.), and then lyophilized at -80°C before use. The immunoglobulin class was determined using a mouse immunoglobulin typing kit (The Binding Site Ltd., Birmingham, U.K.).
Immunoblotting: Following SDS-PAGE on 4-20% gradient gels under non-reducing and reducing conditions, COMP antigen was electrotransferred onto PVDF membranes. After blocking, mAbs 12C4 (against human COMP), as well as mAbs 2A11, 3C8, and 14G4 (against equine COMP) diluted 1:5,000, in 2% skimmed milk in TBS/Tween, were applied to the membrane. Positive binding to COMP was detected using alkaline phosphatase (AP)-conjugated goat anti-mouse IgG antibody (Sigma A3562) diluted 1:10,000 in 2% skimmed milk in TBS/Tween, and demonstrated by development of the reaction with a substrate (BCIP/NBT, Sigma B5655).
ELISA: An inhibition ELISA to quantify COMP was designed according to previous protocol [16] . In brief, purified horse COMP antigen in a coating buffer (20 mM sodium carbonate, 20 mM sodium bicarbonate, 0.002% sodium azide, pH10) was placed into each well at 0.5 µg/ml, incubated for 1 hr at room temperature and then overnight at 4°C. Diluted standards (range: 2.34-0.018 µg/ml) and samples (final dilutions; 1/100 for SF, 1/10 for serum, and 1/10 for urine) were mixed with the same volume of mAbs (final dilution; 1/5,000) in phosphate-buffered saline containing 0.05% Tween 20 (PBS/Tween), and then incubated overnight at 4°C. Coated wells were washed with PBS, blocked, and then incubated with the COMP-antibodies mixture for 1 hr at room temperature and then for 1 hr at 4°C. The primary antibody binding to COMP was detected by AP reaction. One hr later, the production of chromophore was stopped by addition of 2 M H 2 CO 3 , and the absorbance at 405 nm (OD405) was read. Considering that more concen-trated urine would show a higher COMP level, measurements of urinary COMP (µg/ml) were normalized to the urinary creatinine concentration (mg/dl), which was quantified by the Jaffe method (Creatinine Test Wako, 277-10501, Wako Pure Chemical Industries, Ltd., Osaka, Japan), and expressed as the [urinary COMP (µg)]/[urinary creatinine (mg)] ratio.
Statistics: All quantitative group data by ELISA were analysed for normality, and expressed as mean ± standard deviation. The differences in COMP concentrations between the groups (OP(-) vs OP(+)) were analysed by factorial ANOVA, and Scheffé's method was used for simultaneous multiple comparisons. Differences at p<0.05 were considered statistically significant. Correlations of COMP measurements between using the different mAbs in SF, serum, and urine samples, and between the COMP measurements and the period from injury to surgery, were considered statistically significant at p<0.05.
RESULTS
Characterization of monoclonal antibodies:
As shown on the immunoblots (Fig. 1) , mAbs 2A11 and 3C8 bound to both the non-reduced oligomeric and reduced monomeric equine COMP molecules, as did mAbs 14G4, and 12C4, which have been shown to have affinity for equine COMP. As compared with the mAbs for human COMP (12C4 ), our new mAbs 2A11 and 3C8 bound to smaller fragments of COMP that were degraded in the process of purification, as mAb 14G4.
ELISA Measurement of COMP Levels in SF, Serum, and Urine: In the standard curves obtained using both mAbs 2A11 and 3C8, the linear portions for purified COMP were parallel to the inhibition curves obtained by diluting serum, urine and SF (Fig. 2) . The COMP levels in SF, serum, and urine determined by inhibition ELISA showed a significant positive correlation between the two different mAbs (Fig.  3) . There was no significant difference between grade from one to four in the values obtained using SF (70.3 ± 23.3 vs 69.6 ± 27.6 vs 59.7 ± 16.5 vs 70.1 ± 17.8 µg/ml, and 67.8 ± 19.7 vs 57.9 ± 26.1 vs 53.8 ± 22.7 vs 79.0 ± 12.9 µg/ml using mAbs 2A11 and 3C8, respectively), and serum (3.17 ± 0.15 vs 2.97 ± 0.69 vs 3.06 ± 0.49 vs 4.54 ± 2.26 µg/ml, and 1.87 ± 0.48 vs 1.60 ± 0.60 vs 1.72 ± 0.29 vs 2.73 ± 1.73 µg/ml using mAbs 2A11 and 3C8, respectively), and the [urinary COMP]/[urinary creatinine] ratio (3.34 ± 2.85 vs 3.98 ± 4.43 vs 3.46 ± 3.70 vs 7.91 ± 4.36, and 1.02 ± 0.57 vs 1.21 ± 0.98 vs 1.14 ± 1.06 vs 2.20 ± 1.07 using mAbs 2A11 and 3C8, respectively) (Fig. 4) . As shown in Fig. 5 , in which demonstrates COMP measurements determined using mAbs 2A11 and 3C8, there was no significant difference between the OP(+) and OP(-) groups in the values obtained using SF (65.8 ± 20.1 vs 67.21 ± 25.6 µg/ml, and 64.4 ± 24.1 vs 55.6 ± 22.5 µg/ml using mAbs 2A11 and 3C8, respectively), and serum (3.16 ± 1.04 vs 3.12 ± 0.58 µg/ml, and 1.78 ± 0.72 vs 1.75 ± 0.50 µg/ml using mAbs 2A11 and 3C8, respectively). On the other hand, the [urinary COMP]/[urinary creatinine] ratio in OP(+) horses (4.94 ± 5.10 and 1.46 ± 1.19, using mAbs 2A11 and 3C8, respectively) was significantly increased in comparison with OP (-) horses (2.80 ± 1.72 and 0.93 ± 0.49, respectively) (p<0.05, both). In 31 cases for which the day of injury was known, the serum COMP value and the [urinary COMP]/[urinary creatinine] ratio were extrapolated by a polynomial expression between the period from injury to surgery, respectively (Fig. 6 ).
DISCUSSION
Osteochondral fracture is an advantageous model for Fig. 1 . Western blot analysis using specific mAbs against COMP. The oligomeric molecules cross-reacted with mAbs against human COMP (12C4), and were also revealed using mAbs directed against equine COMP (2A11, 3C8 and 14G4). The mAbs against equine COMP showed higher affinity for the lower-molecular-weight monomers, compared with the mAbs against human COMP. investigation of OA pathology, as it is evident arthroscopically and radiographically from the focal stage, when there is no degenerative cartilage around the fracture line or osteophyte (OP(-)), to the expanded stage when definite OP is present, suggesting subchondral bone remodeling (OP(+)). In OA pathology, cartilage degradation and OP formation are pathomonic. OP, a fibrocartilage-capped bony outgrowth, is formed in the early stage of OA. Also, OP is formed at/around the site of a fracture and/or the site of trauma to ligaments or inflammation of the insertion of ligaments and tendons to bone, leading to joint instability. Therefore, OP can form prior to or secondary to fracture, and this means that osteoarthritis can be evaluated in terms of OP formation arthroscopically and radiographically. Two previous studies have investigated COMP concentrations in horses with osteochondral fractures. In carpal SF from acutely lame Thoroughbred racehorses, the COMP concentration was significantly higher in those with osteochondral fracture than in those with OA [18] . Furthermore, intact and fragmented molecules of COMP were present in SF samples from fracture cases and OA cases, respectively [18] . Enhanced fragmentation of SF COMP in accordance with OA development was also demonstrated in our previous study [12] , suggesting that OA was associated with increased enzymatic degradation of COMP in SF. Another study demonstrated enhanced activity of gelatinases (MMP-2 and-9) in SF from fracture cases, and showed that this was significantly correlated with an increased level of urinary COMP [14] . At the advanced stage of OA secondary to intraarticular fracture, enhanced degradation of COMP in SF could increase the fragments flowing out into the bloodstream, and consequently excreted into urine. In the present study comparing the levels of COMP between each grade and between OP(+) and OP(-) cases following osteochondral fractures in the carpal joints of racehorses, there was no significant difference in either SF or serum samples (Figs. 4  and 5 ). This result is not consistent with the increased SF COMP concentration in OA, described previously after car- pal fracture [18] . The level of COMP in SF would differ at various stages from primary injury to the development of OA; the level might increase due to unusual mechanical loading, which might re-injure the cartilage or augment matrix synthesis [18] , whereas it might decrease due to inflammation, through dilution by exudate, or by increased hyperpermeable clearance or proteolytic fragmentation [15, 19] . To confirm increased synthesis and clearance of COMP from injured joints using samples of SF, quantitative evaluation of COMP should be combined with qualitative immunoblot analysis of COMP fragmentation. Interestingly, the urinary COMP level in OP(+) horses was found to be significantly higher than in OP(-) horses, using either mAb 2A11 or 3C8 (Fig. 5 ). Thus, the COMP level in urine appears to be more predictive of OA than that in SF.
To analyse the changes in biomarkers associated with OA secondary to intraarticular fracture, the clinical course (the day of injury, or the duration of lameness before surgery), as well as the arthroscopic and radiographic findings, should be clarified. In the present 31 cases for which the day of injury (fracture) was known, the serum and urinary COMP values were correlated with the period from injury to surgery, but no significant correlation was observed for SF COMP values (Fig. 6) . High serum and urinary COMP levels could indicate enhanced clearance as well as increased synthesis and degradation of COMP, associated with OA progression following fracture. Increased clearance of fragmented COMP from osteoarthritic SF could increase the serum COMP level, and this would lead to a prominent increase in the urinary concentration. The relationship between serum COMP values and the period from injury to surgery could be extrapolated by a polynomial expression (y=-1*10 -8 x 3 +2*10 -4 x 2 -0.02x+3.16, r=0.89, n=31, p<0.001, with 2A11, and y=-1*10 -7 x 3 +2*10 -4 x 2 -0.01x+1.75, r=0.81, n=31, p<0.001, with 3C8), although there was not relationship between the stage of OA and the period from injury to surgery until 100 days after injury. Serum COMP values increased gradually during the advanced stage of OA. The relationship between the urinary COMP level and the period from injury to surgery could also be extrapolated by a polynomial expression (y=-9*10 -6 x 3 +4*10 -3 x 2 -0.30x+7.40, r=0.54, n=31, p<0.01, with 2A11, and y=-2*10 -6 x 3 +7*10 -4 x 2 -0.06x+1.90, r=0.46, n=31, p<0.05, with 3C8). Urinary COMP values changed in a manner similar to SF COMP values. Namely, the urinary COMP level increased from just after injury up to 2 weeks, decreased during the subsequent 3 months, and finally increased again. The COMP levels were especially high in the advanced stage of OA after OP had formed, again suggesting that an increased level of urinary COMP would be a reliable predictor of OA development. Despite the lack of a positive linear regression of SF COMP to the period from injury to surgery, the relationship between the SF COMP level and the period within 2 months after fracture was extrapolated by a polynomial expression (y=0.0033x 3 -0.3371x 2 + 8.7748x + 15.307, r=0.53, n=22, p<0.05, with 2A11, and y=0.0025x 3 -0.2686x 2 + 7.309x + 11.891, r=0.417, n=22, n.s., with 3C8). Following the injury, the SF COMP level initially increased during the first 2 weeks, decreased during the subsequent 2 months, and finally increased again. The increase of the SF COMP level (positive correlation) during the first 2 weeks appears to agree with a previous study that demonstrated a positive lin- with osteophyte (OP positive group; OP(+)) and without osteophyte (OP negative group; OP(-)). There was no significant difference between the OP(+) and OP(-) groups in SF and serum COMP levels, whilst the urinary COMP levels in OP(+) horses were significantly (p<0.05 using mAbs 2A11 and 3C8, both) higher than those in OP(-) horses.
ear correlation (r=0.57, n=13, p=0.04) between SF COMP concentration and duration of lameness before surgery in horses with fractures within 2 weeks of durative lameness [18] . The subsequent decrease in the SF COMP level (negative correlation) until 2 months after fracture also appears to correspond to results of our earlier study [14] , in which we speculated that SF COMP levels could be higher in the acute phase of fracture, but then gradually decrease in accordance with increased proteolysis in SF during the stage of OA development. Finally, at the severe or late stage of OA, the SF COMP level might again increase, as the polynomial curve turned up again on a turning point (3 months after fracture).
Our new mAbs 2A11 and 3C8 recognized the same COMP oligomers from equine articular cartilage as those recognized by mAb12C4, while showing higher affinity for the more degraded small fragments of COMP monomer than for the less-degraded large molecular fragments. The higher affinity of the new mAbs for the small monomer molecules suggests that their epitopes might also be less affected by proteolysis of the COMP molecule, as hypothesized in our previous study using mAb 14G4 [12] . COMP concentration in horses has been determined previously with various ELISA systems employing different purities of antigenic COMP, antibodies, and procedures. The levels of COMP in SF of the distal interphalangeal joint, the metacarpophalangeal joint and the navicular bursa in normal horses have been reported to be 58.0 ± 12.3, 23.4 ± 4.2, and 43.5 ± 6.3 µg/ml, respectively [20] . The mean SF COMP concentration in the normal tarsometatarsal joint is reportedly 24.5 µg/ml [19] . Using mAb 12C4 raised against human COMP, the mean SF COMP level in various normal joints was reported to be 53.2 ± 29.0 µg/ml [16] . We have also found a higher COMP level (133.1 ± 31.5 µg/ml) in normal SF from various joints using the mAb 14G4 [12] . ELISA with the new mAbs 2A11 and 3C8 also gave COMP levels of 49.4 ± 21.4 and 43.1 ± 19.1 µg/ml, respectively, in 95 samples of normal SF (preliminary data). Another report has documented a higher SF COMP concentration in carpal osteochondral fragments from racing Thoroughbreds (40 ± 25 µg/ml) than in SF from normal carpal joints (22 ± 10 µg/ ml) [18] . In the present study, SF COMP measurements in horses with carpal bone fractures might also have been higher than normal, using either of the mAbs. To minimize differences among laboratories or researchers, the assay system for determination of equine COMP should be made available in a commercial kit form.
The mean COMP levels in serum compared to those in SF were 4.7% vs 4.5% (OP (+) vs OP(-)) determined with mAb 2A11, and 2.7% vs 3.0% (OP(+) vs OP(-)) determined with mAb 3C8, and there was no significant correlation between the SF and serum levels. Our previous study using mAb 14G4 also demonstrated no significant correlation between SF and serum levels of COMP in cases of aseptic joint dis- Fig. 6 . Scattergrams showing the relationship between COMP measurements and the period from injury to surgery, in cases where the day of injury was known. The relationship between serum and urinary COMP levels and the period after injury to surgery respectively, were extrapolated by a polynomial expression, whilst the measurements obtained using synovial fluid (SF) showed no significant correlation.
ease [14] . We previously speculated that the increase in the serum COMP level relative to the SF level might be modest due to effective dilution by blood volume, and might also be further obscured by a non-specific factor present during daily activity [13] . In the present study, we found an extrapolation to a polynomial expression between the serum level of COMP and the period from injury to surgery, despite the lack of a significant difference in the serum level between OP(-) and OP(+) horses. This indicates that the serum level of COMP might have potential use as an indicator of OA pathology in racehorses with carpal joint trauma, if the serum is sampled at rest. There was also an extrapolation to a polynomial expression between the urinary COMP level and the period from injury to surgery, in addition to a significant difference in the urinary COMP level between OP(-) and OP(+) horses, in contrast to the serum level. In cases of intraarticular fracture in a carpal joint, COMP values, in particular the urinary level, would not correlate with the severity and/or extent of joint trauma, and would change in accordance with the stage of OA prior to or secondary to injury. Our present data indicate that the urinary level of COMP is more dependent on OA pathology following carpal fracture than the serum level.
